Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy

NCT06696456 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-04-06

No results posted yet for this study

Summary

This multi-center, observational, post-intervention long term follow-up (LTFU) study will monitor for safety and efficacy of AAVAnc80-hOTOF in individuals with sensorineural hearing loss due to otoferlin gene mutations who have previously received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial.

Conditions

  • Otoferlin Gene-mediated Hearing Loss

Sponsors & Collaborators

Principal Investigators

  • Peter Marks, M.D. · Eli Lilly and Company

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-11
Primary Completion
2033-04-30
Completion
2033-04-30

Countries

  • United States
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06696456 on ClinicalTrials.gov